Clinical Trial Update: Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed [Phase 2]

View source ↗

Summary

Phase 2 trial of thalidomide in combination with interferon alfa in patients with unresectable progressive liver cancer (hepatocellular carcinoma) has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Interferon Alfa (interferon alfa)
• Thalidomide (thalidomide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED